Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 7/20 | 0.42 |
| ▸ | IDE | P14735 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 4/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21592287 | 0.90 | CYP19A1 (0.52) | IDH1GSK3BIDEQPCT | |
| SCHEMBL21592259 | 0.87 | IDH1 (0.41) | IDH1GSK3BIDEQPCTTSHR | |
| SCHEMBL21592240 | 0.81 | KMT2A (0.49) | GSK3BIDEQPCTKMT2A | |
| SCHEMBL21591502 | 0.81 | CYP11B1 (0.59) | KMT2A | |
| SCHEMBL21591454 | 0.78 | CYP11B1 (0.58) | KMT2A | |
| SCHEMBL21591444 | 0.77 | CYP11B1 (0.42) | TSHRKMT2A | |
| SCHEMBL21592249 | 0.76 | CYP11B1 (0.41) | GSK3BQPCTKMT2A | |
| SCHEMBL21592272 | 0.76 | NPC1 (0.48) | KMT2A | |
| SCHEMBL21591439 | 0.74 | CYP11B1 (0.37) | TSHRKMT2A | |
| SCHEMBL21591521 | 0.72 | CYP11B1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | Ryvu Therapeutics S.A. (PL) | 2024-12-10 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2022-12-22 | — | — | US | disclosed |
| WO-2019238786-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2019-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162863-B2 | Modulators of stimulator of interferon genes (STING) | STING1, IRF3, CGAS | IDH1 4176/4885GSK3B 705/4885IDE 2903/4885 |
| US-20220402898-A1 | MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | IDH1 4176/4885GSK3B 705/4885IDE 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.